StockData
Nomad Power Solutions, Inc. logo

Nomad Power Solutions, Inc. (NMAD) stock

NMADNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 4/30
$2.85−0.15 (-5.00%)

Close on Nov 18, 2026Market cap $45.89MP/E –Yield –

Key statistics

Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026

Valuation

Market cap
$45.89M
P/E ratio
–
Price to sales
–
Price to book
1.92
Dividend yield
–
Free cash flow yield
–

Fundamentals

Net income
-$6.08M
EPS, diluted
-$1.00
Book value per share
$1.77
Diluted shares
13M

Trading

Previous close
$3.00
Open
$2.96
Day's range
$2.54 – $2.99
Volume
347,117
Average volume (20 days)
269,395
52-week range
$2.15 – $8.38
RSI (14 days)
38.8
Volatility (1 year)
104.2%
Relative volume
1.31×

Market cap history

Month-end market cap since 2011, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 18, 2026. The S&P 500 is measured by the SPY fund.

PeriodNMADS&P 500DifferenceNMAD per yearS&P 500 per year
1 month-26.5%-4.3%−22.2 pts
3 months-32.5%-4.6%−27.8 pts
Year to date-27.5%+7.9%−35.4 pts
1 year-34.3%+11.8%−46.1 pts
3 years-5.0%+68.0%−73.0 pts-1.7%+18.9%
5 years-83.4%+66.2%−149.6 pts-30.2%+10.7%
10 years-76.2%+291.3%−367.6 pts-13.4%+14.6%

Fifteen years at a glance

Fiscal years 2011 to 2025 and trailing twelve months, USD

Revenue

–

Gross profit

–

Operating income

-$7.96M

Net income

–

EPS, diluted

-$1.00
Reported periodTrailing twelve months

Press releases

Releases Nomad Power Solutions filed with the SEC as exhibits to Form 8-K or 6-K

All press releases and earnings

About Nomad Power Solutions

Pharmaceutical Preparations

Lixte Biotechnology Holdings, Inc. is a clinical-stage biopharmaceutical and proton therapy enterprise focused on discovering, developing, and commercializing cancer therapies. The organization centers its primary pharmaceutical pipeline on inhibitors of protein phosphatase 2A, targeting their capability to augment the effectiveness of chemotherapy, radiation, and immunotherapy treatments. Its principal investigational asset, designated as LB-100, is undergoing evaluation across several clinical trials, including investigations for ovarian clear cell carcinoma, metastatic colon cancer, and advanced soft tissue sarcoma. In parallel, through its majority ownership in Liora Technologies Europe Ltd., the company develops electronically controlled proton therapy equipment using proprietary linear accelerator systems for tumor radiation.

Company profile, executives and history

Nomad Power Solutions stock: common questions

What is Nomad Power Solutions's stock price?

NMAD closed at $2.85 on Nov 18, 2026, down 5.00% on the day. Over the past 52 weeks it traded between $2.15 and $8.38.

What is Nomad Power Solutions's market cap?

Nomad Power Solutions was worth $45.89M at the close on Nov 18, 2026: the share price times the diluted shares outstanding.

What is NMAD's P/E ratio?

Nomad Power Solutions lost money over the twelve months to Jun 30, 2026 (diluted EPS -$1.00), so it has no meaningful P/E ratio.

Does Nomad Power Solutions pay a dividend?

No. Nomad Power Solutions has not paid a cash dividend over the last twelve months.

How has NMAD stock performed over the past year?

Including dividends, NMAD returned -34.3% over the past year, against +11.8% for the S&P 500.

How many NMAD shares are sold short?

1M shares were sold short at the latest FINRA report, 6.14% of the float, or 4.2 days of average trading volume.

Who are Nomad Power Solutions's competitors?

Companies most similar to Nomad Power Solutions by business, industry and size include SLS, LSTA, KZIA, NBP, APLM.

See a number that looks wrong?